{
  "nctId": "NCT04059770",
  "briefTitle": "Randomized Trial of Liposomal Amphotericin B for Histoplasmosis in AIDS Patients",
  "officialTitle": "Open Label Phase-II Randomized Trial of Three Liposomal Amphotericin B Regimens as Induction Therapy for Disseminated Histoplasmosis in AIDS Patients",
  "protocolDocument": {
    "nctId": "NCT04059770",
    "filename": "Prot_SAP_000.pdf",
    "label": "Study Protocol and Statistical Analysis Plan",
    "date": "2021-02-24",
    "uploadDate": "2024-02-21T12:10",
    "size": 556864,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04059770/document/Prot_SAP_000.pdf",
    "hasProtocol": true,
    "hasSap": true,
    "hasIcf": false
  },
  "phase": [
    "PHASE2"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 118,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-02-14",
    "completionDate": "2022-03-30",
    "primaryCompletionDate": "2021-12-31",
    "firstSubmitDate": "2019-04-01",
    "firstPostDate": "2019-08-16"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Adult (\\> 18 years) HIV-infected hospitalized patients diagnosed with HD by the means of (i) urine Histoplasma positive antigen (IMMY® monoclonal antibody test); (ii) confirmation by classical mycological methods (microscopy, culture or histopathology); or (iii) Histoplasma positive qualitative polymerase chain reaction (PCR) in bronchoalveolar lavage samples, bone marrow aspirates or tissue samples.\n* Patients will be included despite of the use of antiretroviral therapy (ART).\n* Understanding and signed the Informed Consent Form.\n\nExclusion Criteria:\n\n* Patients with previous diagnosis of histoplasmosis.\n* Pregnant or lactating women.\n* Patients with renal insufficiency (serum creatinine and urea \\> 1.5x the upper limit of normal).\n* Abnormal aminotransferases (up to \\> 3x the upper limit of normal) and patients with a severe prior reaction to polyene antifungal.\n* Patients who have received more than one dose of a polyene antifungal in the last 48 hours.\n* Patients who refuse to participate in the study.\n* Patients diagnosed with histoplasmosis that affect the central nervous system.\n* Patients who, at the trial of the attending physician, are expected to die within 48 hours.\n* Patients diagnosed with tuberculosis.\n* Patients with any disease or condition that, in the opinion of the investigator, may interfere with the assessments or participation in the study.\n* Patients receiving drugs that cause significant (relative or absolute) drug interaction with Itraconazole.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Clinical Response",
        "description": "Maximum daily temperature lower than 37.8 °C",
        "timeFrame": "day 14"
      }
    ],
    "secondary": [
      {
        "measure": "Overall Mortality",
        "description": "Mortality rates attributed to the cause of death that is not directly and only related to histoplasmosis",
        "timeFrame": "day 14"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 1,
      "otherCount": 0,
      "totalCount": 2
    },
    "studyDesign": {
      "phases": [
        "PHASE2"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 29,
    "complexityCategory": "Moderate"
  },
  "collectionDate": "2025-09-22T02:30:20.888Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}